Latest Competition News

Raiz Invest Limited has reported record first-quarter FY26 results, hitting $2 billion in funds under management and expanding its customer base to over 335,000. The fintech firm also raised its earnings guidance, underpinned by new product launches and strategic partnerships.

Native Mineral Resources and Great Divide Mining have agreed to jointly develop and process ore from the Yellow Jack Gold Project at NMR’s Blackjack Plant, aiming to enhance regional gold production.

Etherstack has secured a £14.2 million contract with the UK Home Office to provide critical software for the Emergency Services Network, reinforcing its global leadership in public safety communications.

HUB24 has reported a record $5.2 billion in net inflows for Q1 FY26, boosting its Funds Under Administration to $146.5 billion and securing the top spot for adviser satisfaction in Australia.

Evolution Energy Minerals has fast-tracked its Chilalo Graphite Project in Tanzania, aiming to begin ore mining by late 2027 amid strong government partnership and advancing financing talks.

Peppermint Innovation is repositioning as a digital wallet operator targeting the vast Philippine cooperative sector, aiming to scale rapidly and generate predictable revenue from one million active users.

Gold Mountain Limited has reported significant extensions to its rare earth mineralisation at the Irajuba Down Under Project in Brazil, confirming high-grade total and magnet rare earth oxides and paving the way for resource drilling.

Super Retail Group has appointed Paul Bradshaw as its new Group Managing Director and CEO, with Michael Wassman stepping up to lead BCF. These leadership moves underscore the company’s commitment to continuity and growth.

Vonex Limited has finalized its Scheme of Arrangement, transferring all shares to Maxo Telecommunications and initiating a board overhaul ahead of its imminent ASX delisting.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

United States Antimony Corporation has made a non-binding indicative offer to acquire Larvotto Resources at a significant premium, proposing a strategic merger focused on antimony supply chain security and growth.